DE19800812A1 - Verbesserte orale Darreichungsformen von L-Arginin und seinen Derivaten - Google Patents
Verbesserte orale Darreichungsformen von L-Arginin und seinen DerivatenInfo
- Publication number
- DE19800812A1 DE19800812A1 DE1998100812 DE19800812A DE19800812A1 DE 19800812 A1 DE19800812 A1 DE 19800812A1 DE 1998100812 DE1998100812 DE 1998100812 DE 19800812 A DE19800812 A DE 19800812A DE 19800812 A1 DE19800812 A1 DE 19800812A1
- Authority
- DE
- Germany
- Prior art keywords
- arginine
- dosage form
- oral dosage
- effervescent
- hypercholesterolemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 title claims abstract description 18
- 229930064664 L-arginine Natural products 0.000 title claims abstract description 18
- 235000014852 L-arginine Nutrition 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims description 21
- 208000035150 Hypercholesterolemia Diseases 0.000 title description 2
- 208000019622 heart disease Diseases 0.000 title 1
- 235000015097 nutrients Nutrition 0.000 title 1
- 239000002253 acid Substances 0.000 claims abstract description 7
- 239000006186 oral dosage form Substances 0.000 claims description 12
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical group Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 238000012937 correction Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 150000001483 arginine derivatives Chemical class 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
- 240000000902 Diospyros discolor Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Description
Wenn die Verabreichung in Form von Tabletten mit sehr großem Umfang erfolgt, ist die orale Aufnahme durch verminderte Schluckbarkeit stark beeinträchtigt. Wenn sie in Form von Tabletten mit üblicher Größe erfolgt, führt das dazu, daß der Patient zu überdurchschnittlich häufiger Arzneimitteleinnahme gezwungen wird, um eine ausreichende Wirkstoffmenge aufzunehmen. Die Patientencompliance ist dementsprechend gering.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1998100812 DE19800812C2 (de) | 1998-01-12 | 1998-01-12 | Verbesserte orale Darreichungsformen von L-Arginin-HCl |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1998100812 DE19800812C2 (de) | 1998-01-12 | 1998-01-12 | Verbesserte orale Darreichungsformen von L-Arginin-HCl |
Publications (2)
Publication Number | Publication Date |
---|---|
DE19800812A1 true DE19800812A1 (de) | 1999-07-15 |
DE19800812C2 DE19800812C2 (de) | 2000-05-11 |
Family
ID=7854378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1998100812 Expired - Lifetime DE19800812C2 (de) | 1998-01-12 | 1998-01-12 | Verbesserte orale Darreichungsformen von L-Arginin-HCl |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE19800812C2 (de) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001054686A2 (en) * | 2000-01-28 | 2001-08-02 | The Procter & Gamble Company | L-arginine in combination with other compounds for treating cardiovascular diseases |
WO2001055098A1 (en) * | 2000-01-28 | 2001-08-02 | The Procter & Gamble Company | Palatable arginine compounds and uses thereof for cardiovascular health |
WO2001097635A2 (en) * | 2000-06-20 | 2001-12-27 | Coraltis Ltd. | Microcapsules containing arginine and the different uses thereof |
DE10128934A1 (de) * | 2001-06-18 | 2003-02-06 | Bernhard Sibbe | Wirkstoffzusammensetzung zur Vorbeugung gegen Angina-Pectoris-Beschwerden |
EP1310174A1 (de) * | 2001-11-07 | 2003-05-14 | Hikari Seika Co., Ltd. | Zusammensetzung zur Verbesserung von Geschmack |
EP2247278A2 (de) * | 2008-02-08 | 2010-11-10 | Colgate-Palmolive Company | Reinigungsmittel und verfahren |
EP2249776A2 (de) * | 2008-02-08 | 2010-11-17 | Colgate-Palmolive Company | Brausezusammensetzungen |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0567433A1 (de) * | 1992-04-23 | 1993-10-27 | Sandoz Nutrition Ltd. | Zusammensetzungen zur oralen Nahrungsmittelaufnahme mit verbessertem Geschmack |
DE3725176C2 (de) * | 1986-08-01 | 1995-06-14 | Zambon Spa | Pharmazeutische Zusammensetzung mit analgetischer Aktivität |
DE3638414C2 (de) * | 1985-11-12 | 1996-03-28 | Zambon Spa | Pharmazeutische Zusammensetzung mit analgetischer Wirkung |
-
1998
- 1998-01-12 DE DE1998100812 patent/DE19800812C2/de not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3638414C2 (de) * | 1985-11-12 | 1996-03-28 | Zambon Spa | Pharmazeutische Zusammensetzung mit analgetischer Wirkung |
DE3725176C2 (de) * | 1986-08-01 | 1995-06-14 | Zambon Spa | Pharmazeutische Zusammensetzung mit analgetischer Aktivität |
EP0567433A1 (de) * | 1992-04-23 | 1993-10-27 | Sandoz Nutrition Ltd. | Zusammensetzungen zur oralen Nahrungsmittelaufnahme mit verbessertem Geschmack |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6794375B2 (en) | 2000-01-28 | 2004-09-21 | The Procter & Gamble Co. | Palatable arginine compounds and uses thereof for cardiovascular health |
WO2001055098A1 (en) * | 2000-01-28 | 2001-08-02 | The Procter & Gamble Company | Palatable arginine compounds and uses thereof for cardiovascular health |
WO2001054686A3 (en) * | 2000-01-28 | 2002-05-02 | Procter & Gamble | L-arginine in combination with other compounds for treating cardiovascular diseases |
WO2001054686A2 (en) * | 2000-01-28 | 2001-08-02 | The Procter & Gamble Company | L-arginine in combination with other compounds for treating cardiovascular diseases |
WO2001097635A2 (en) * | 2000-06-20 | 2001-12-27 | Coraltis Ltd. | Microcapsules containing arginine and the different uses thereof |
WO2001097635A3 (en) * | 2000-06-20 | 2002-04-11 | Coraltis Ltd | Microcapsules containing arginine and the different uses thereof |
DE10128934A1 (de) * | 2001-06-18 | 2003-02-06 | Bernhard Sibbe | Wirkstoffzusammensetzung zur Vorbeugung gegen Angina-Pectoris-Beschwerden |
EP1310174A1 (de) * | 2001-11-07 | 2003-05-14 | Hikari Seika Co., Ltd. | Zusammensetzung zur Verbesserung von Geschmack |
EP2247278A2 (de) * | 2008-02-08 | 2010-11-10 | Colgate-Palmolive Company | Reinigungsmittel und verfahren |
EP2249776A2 (de) * | 2008-02-08 | 2010-11-17 | Colgate-Palmolive Company | Brausezusammensetzungen |
EP2249776A4 (de) * | 2008-02-08 | 2014-01-08 | Colgate Palmolive Co | Brausezusammensetzungen |
EP2247278A4 (de) * | 2008-02-08 | 2014-02-19 | Colgate Palmolive Co | Reinigungsmittel und verfahren |
US10959967B2 (en) | 2008-02-08 | 2021-03-30 | Colgate-Palmolive Company | Effervescent compositions |
Also Published As
Publication number | Publication date |
---|---|
DE19800812C2 (de) | 2000-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3779500T2 (de) | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. | |
DE3638414C2 (de) | Pharmazeutische Zusammensetzung mit analgetischer Wirkung | |
DE68905096T2 (de) | Niacin und guar-mehl enthaltende zusammensetzung. | |
DE3435040A1 (de) | Pharmazeutische zusammensetzung, geeignet zur behandlung von hang-over-symptomen | |
DE68923819T2 (de) | Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen. | |
DE69016541T2 (de) | Nichtsprudelnde Ibuprofen-Zusammensetzungen. | |
DE69913116T2 (de) | Orale flüssige lösung enthaltend das antidepressivum mirtazapine | |
DE60204712T2 (de) | Zubereitung enthaltend paracetamol und ein geschmacksmaskierungsmittel | |
EP2886108B2 (de) | Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus | |
DE69605531T2 (de) | Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans | |
DE19800812C2 (de) | Verbesserte orale Darreichungsformen von L-Arginin-HCl | |
DE1767017B2 (de) | Steckkapsel-Eisenpräparat | |
WO2021013283A1 (de) | Mundhygienemittel enthaltend koffein und l-lysin als bitterblocker | |
EP0349797B1 (de) | Stabilisierte, N-acetylcysteinhaltige Arzneimittelzubereitung | |
EP1073469B1 (de) | Stabile mitoxantron-lösungen | |
WO2019201707A1 (de) | Stoffgemisch umfassend k-mg-citrat zur verwendung als arzneimittel | |
DE60207442T2 (de) | VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION | |
DE60133284T2 (de) | Medizinisches kombinationspräparat zur behandlung von verletztem abnormem gewebe | |
JP4959864B2 (ja) | グルタミン酸塩含有液剤 | |
EP1150660B1 (de) | Pharmazeutische, metamizol enthaltende brauseformulierung | |
CN112891303A (zh) | 一种普瑞巴林口服溶液及其制备方法 | |
JPH0473411B2 (de) | ||
DE60209269T2 (de) | Methode zur Prävention der Frühgeborenenretinopathie beim Neugeborenen | |
US3995057A (en) | Ophthalmological method | |
Moore et al. | Bromide Intoxication. pp 1–13 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
D2 | Grant after examination | ||
8363 | Opposition against the patent | ||
8365 | Fully valid after opposition proceedings | ||
R008 | Case pending at federal patent court | ||
R082 | Change of representative |
Representative=s name: VOSSIUS & PARTNER, DE |
|
R081 | Change of applicant/patentee |
Owner name: FBR ARZNEIMITTEL GMBH, DE Free format text: FORMER OWNERS: FROELICH, JUERGEN C., PROF. DR.MED., 31832 SPRINGE, DE; BRACHT, KLAUS, 58507 LUEDENSCHEID, DE Effective date: 20120918 Owner name: FBR ARZNEIMITTEL GMBH, DE Free format text: FORMER OWNER: JUERGEN C. FROELICH,KLAUS BRACHT, , DE Effective date: 20120918 Owner name: FROELICH, JUERGEN C., PROF. DR.MED., DE Free format text: FORMER OWNER: JUERGEN C. FROELICH,KLAUS BRACHT, , DE Effective date: 20120918 Owner name: JUERGEN C. FROELICH, DE Free format text: FORMER OWNER: JUERGEN C. FROELICH,KLAUS BRACHT, , DE Effective date: 20120918 |
|
R082 | Change of representative |
Representative=s name: VOSSIUS & PARTNER PATENTANWAELTE RECHTSANWAELT, DE Effective date: 20120918 Representative=s name: VOSSIUS & PARTNER, DE Effective date: 20120918 |
|
R039 | Revocation action filed |
Effective date: 20120827 |
|
R082 | Change of representative |
Representative=s name: VOSSIUS & PARTNER, DE |
|
R081 | Change of applicant/patentee |
Owner name: FBR ARZNEIMITTEL GMBH, DE Free format text: FORMER OWNER: FROELICH, JUERGEN C., PROF. DR.MED., 31832 SPRINGE, DE Effective date: 20121128 |
|
R082 | Change of representative |
Representative=s name: VOSSIUS & PARTNER PATENTANWAELTE RECHTSANWAELT, DE Effective date: 20121128 Representative=s name: VOSSIUS & PARTNER, DE Effective date: 20121128 |
|
R020 | Patent grant now final | ||
R120 | Application withdrawn or ip right abandoned |
Effective date: 20140310 |
|
R040 | Withdrawal/refusal of revocation action now final |
Effective date: 20140310 |